Related Experiment Video
Updated: Aug 10, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Intracellular polymerization. Disease severity and therapeutic predictions
C T Noguchi1, G P Rodgers, A N Schechter
1Laboratory of Chemical Biology, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892.
Annals of the New York Academy of Sciences
|January 1, 1989
Summary
Intracellular polymerization of hemoglobin S causes sickle cell disease. Increasing hemoglobin F levels may reduce sickling and improve disease severity, with hydroxyurea showing promise.
Area of Science:
- Hematology
- Molecular Biology
- Biophysics
Background:
- Sickle cell disease pathogenesis involves intracellular polymerization of hemoglobin S (HbS).
- Polymerization is influenced by oxygen saturation, HbS concentration, and composition.
- Therapeutic strategies aim to inhibit HbS polymerization or reduce its intracellular concentration.
Purpose of the Study:
- To evaluate the clinical benefit of therapeutic strategies targeting sickle cell disease.
- To assess the impact of increasing non-S hemoglobin levels, particularly hemoglobin F (HbF), on HbS polymerization.
- To analyze the relationship between HbF levels and sickle cell disease severity.
Main Methods:
- Epidemiological analysis of sickle cell disease severity.
- Biophysical studies of intracellular HbS polymerization.
- Analysis of equilibrium polymer formation at physiological oxygen saturation.
Main Results:
- Increasing HbF levels inhibits HbS polymerization, potentially reducing disease severity.
- Small decreases in polymerization at intermediate HbF levels may slightly reduce anemia.
- Significant improvements in disease severity may require greater reductions in HbS polymer formation.
Conclusions:
- Increasing HbF is a promising therapeutic strategy for sickle cell disease.
- Hydroxyurea shows potential for inducing therapeutically beneficial HbF levels.
- Further research is needed to optimize HbF-inducing therapies for substantial clinical benefit.
Related Concept Videos
01:31Types of Intermediate Filaments
The intermediate filaments are an essential component of the cytoskeleton. Presently six types of intermediate filament have been identified. Type I and II are acidic and basic keratin proteins. Type III is of mesodermal origin and comprises four proteins: vimentin, desmin, glial fibrillary acidic protein (GFAP), and peripherin. Vimentin is commonly found in mesenchymal cells, desmin in muscle cells, GFAP in astrocytes, while peripherin is found in peripheral nervous system neurons (PNS). Type...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...